Vonoprazan noninferior to PPIs in preventing 30-day rebleeding in high-risk peptic ulcers
Vonoprazan was noninferior to high-dose IV proton pump inhibitor therapy in preventing 30-day rebleeding among patients with high-risk peptic ulcer bleeding who had achieved endoscopic hemostasis, according to data. “Efficacy of vonoprazan has been demonstrated as noninferior to PPIs in various acid-related diseases, including erosive esophagitis, Helicobacter pylori eradication therapy,